Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | HCK | P08631 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697113 | 0.94 | POLB (0.59) | BRAFLCKKDRINSRLYN | |
| SCHEMBL4917626 | 0.93 | BRAF (0.58) | BRAFKDRBTKPOLBABL1 | |
| SCHEMBL4917112 | 0.92 | BRAF (0.47) | BRAFLCKKDRINSRLYN | |
| SCHEMBL4787068 | 0.90 | BRAF (0.57) | BRAFKDRBTKPOLBABL1 | |
| SCHEMBL4696070 | 0.87 | BRAF (0.57) | BRAFCSF1RKIT | |
| SCHEMBL4697700 | 0.87 | BRAF (0.63) | BRAFLCKKDRINSRLYN | |
| SCHEMBL4697939 | 0.86 | BRAF (0.54) | BRAFLCKKDRINSRLYN | |
| SCHEMBL4697821 | 0.86 | BRAF (0.62) | BRAFLCKKDRINSRLYN | |
| SCHEMBL4696782 | 0.86 | BRAF (0.57) | BRAFCSF1RKIT | |
| SCHEMBL4698765 | 0.86 | BRAF (0.61) | BRAFLCKKDRINSRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | BRAF 42/4885LCK 35/4885KDR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.